Harvard Bioscience, Inc. (HBIO) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

19/25

Growth 5 Margin 3 Expansion 5 Platform 3 Financial 3

latest quarter score

Earnings Reports

19
HBIO Q2 2026: 11% Revenue Growth Driven by CMT and China Expansion, Raising Full-Year Guidance
August 11, 2026
17
Harvard Bioscience (HBIO) Q1 2026: NPI Revenue Rises to 20%, Margin Path Clears for 60%+
June 17, 2026
18
Harvard Bioscience (HBIO) Q4 2025: Gross Margin Expands 260bps as Product Mix and Cost Actions Reshape Core
June 17, 2026
13
Harvard Bioscience (HBIO) Q2 2025: Cash Flow Jumps to $2.8M as Cost Actions Offset Revenue Dip
June 16, 2026
18
Harvard Bioscience (HBIO) Q3 2025: Backlog Hits Two-Year High as Margin Expands 200bps
June 16, 2026
21
Harvard Bioscience (HBIO) Q4 2025: Gross Margin Hits 60% as Platform Shift Accelerates Recurring Revenue
June 15, 2026
14
Harvard Bioscience (HBIO) Q1 2025: $48M Goodwill Impairment Highlights Strategic Reset Amid Revenue Pressure
May 12, 2025
12
Harvard Bioscience (HBIO) Q4 2024: 12% Sequential Revenue Growth Highlights Product Traction Amid Market Challenges
March 12, 2025

Browse all companies